^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    GENE:

    EVI2B (Ecotropic Viral Integration Site 2B)

    i
    Other names: EVI2B, Ecotropic Viral Integration Site 2B, EVDB, D17S376, CD361, Ecotropic Viral Integration Site 2B Protein Homolog, Protein EVI2B, EVI-2B, CD361 Antigen
    Associations

    News

    Trials
    8ms
    Identifying Molecular Modulators of the Vascular Invasion in Rectal Carcinoma: Role of ADAMTS8 and Its Co-Dependent Genes. (PubMed, Int J Mol Sci)
    Ultimately, we identified four high-affinity compounds-cyanoginosin LR, doxorubicin, benzo[a]pyrene, and dibenzo(a,e)pyrene-that interacted with all target proteins. These compounds show potential for further assessment of their role in modulating processes related to vascular invasion, which is a strong negative predictor of RC outcomes.
    Journal
    |
    EVI2B (Ecotropic Viral Integration Site 2B) • SOX4 (SRY-Box Transcription Factor 4)
    |
    doxorubicin hydrochloride
    12ms
    Utility of a Large Series of B-Cell Precursor Acute Lymphoblastic Leukemia Cell Lines as a Model System. (PubMed, Cancer Med)
    Large series of BCP-ALL cell lines is a powerful research tool for studying the mechanisms of leukemogenesis and the disease progression of BCP-ALL.
    Preclinical • Journal
    |
    CCNE1 (Cyclin E1) • HDAC2 (Histone deacetylase 2) • EVI2B (Ecotropic Viral Integration Site 2B) • MAD2L1 (Mitotic Arrest Deficient 2 Like 1) • YWHAG (Tyrosine 3-Monooxygenase/Tryptophan 5-Monooxygenase Activation Protein Gamma)
    1year
    Exploring potential causal genetic variants and genes for endometrial cancer: Open Targets Genetics, Mendelian randomization, and multi-tissue transcriptome-wide association analysis. (PubMed, Transl Cancer Res)
    We confirmed the involvement of EVI2A in the pathogenesis of EC and identified several other genes that may contribute to EC development. These findings offer new insights into the genetic mechanisms underlying EC and may inform future research and therapeutic strategies.
    Journal
    |
    NF1 (Neurofibromin 1) • EVI2B (Ecotropic Viral Integration Site 2B)
    1year
    Research on the influence of radiotherapy-related genes on immune infiltration, immunotherapy response and prognosis in melanoma based on multi-omics. (PubMed, Front Immunol)
    Our findings highlight the critical role of RT-related genes in predicting SKCM prognosis and guiding personalized therapy strategies, particularly in the context of immunotherapy. These contribute to understanding the role of radiotherapy combined with immunotherapy in melanoma.
    Journal • IO biomarker
    |
    CXCL13 (Chemokine (C-X-C motif) ligand 13) • DUSP1 (Dual Specificity Phosphatase 1) • EVI2B (Ecotropic Viral Integration Site 2B) • SLAMF7 (SLAM Family Member 7)
    over1year
    Impact of Introducing Anchor ed Multiplex NGS Assays for the Detection of Novel Fusion Partners and Variants in Acute Lymphoblastic Leukemia, Lymphoma, and Sarcoma: Snapshot of a Cohort of Lebanese Patients (AMP Europe 2024)
    The ability to detect these characteristic fusions ensures an accurate diagnosis and prognosis, and guides treatment decisions, molecular classificati on, and disease monitoring. Using NGS presents several advantages ov er standard testing methods, as it allows for the simultaneous analysis of multiple targets, thus saving time and testing material. It subsequently allows the incorporation of newly discovered biomarkers in the era of precision medicine.
    Clinical • IO biomarker • Next-generation sequencing
    |
    KRAS (KRAS proto-oncogene GTPase) • ALK (Anaplastic lymphoma kinase) • ABL1 (ABL proto-oncogene 1) • NRAS (Neuroblastoma RAS viral oncogene homolog) • BCL2 (B-cell CLL/lymphoma 2) • NPM1 (Nucleophosmin 1) • MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • RUNX1 (RUNX Family Transcription Factor 1) • KMT2A (Lysine Methyltransferase 2A) • BCL6 (B-cell CLL/lymphoma 6) • ETV6 (ETS Variant Transcription Factor 6) • CRLF2 (Cytokine Receptor Like Factor 2) • IKZF1 (IKAROS Family Zinc Finger 1) • EWSR1 (EWS RNA Binding Protein 1) • PAX5 (Paired Box 5) • AFF1 (AF4/FMR2 Family Member 1) • JAK3 (Janus Kinase 3) • IRF8 (Interferon Regulatory Factor 8) • TCF3 (Transcription Factor 3) • PBX1 (PBX Homeobox 1) • FOXP1 (Forkhead Box P1) • EVI2B (Ecotropic Viral Integration Site 2B) • PAX3 (Paired Box 3)
    |
    Archer® FusionPlex® Acute Lymphoblastic Leukemia (ALL)
    over2years
    Establishing and Validating an Aging-Related Prognostic Signature in Osteosarcoma. (PubMed, Stem Cells Int)
    A nomogram combining ARG-based risk signature and metastatic status was established, showing great prediction accuracy and clinical benefit for osteosarcoma OS. We characterized three ARG-based molecular subtypes with distinct characteristics and built an ARG-based risk signature for osteosarcoma prognosis, which could facilitate prognosis prediction and making personalized treatment in osteosarcoma.
    Journal • IO biomarker
    |
    SSX1 (SSX Family Member 1) • EVI2B (Ecotropic Viral Integration Site 2B) • SLC17A9 (Solute Carrier Family 17 Member 9)
    over2years
    EVI2B may be a novel prognostic marker for lung adenocarcinoma. (PubMed, Biomark Med)
    EVI2B overexpression constrained LUAD cell viability, migration and invasion. EVI2B was related to prognosis and immune microenvironment in LUAD, suggesting that EVI2B may be a novel prognostic marker for LUAD.
    Journal
    |
    EVI2B (Ecotropic Viral Integration Site 2B)
    over2years
    The Impact of Genomics to Identify Novel Immunotherapeutic Targets in Multiple Myeloma (IMW 2023)
    Our studies demonstrated the existence of novel increased expression of genes encoding surface proteins in NDMM patient samples that maintained their expression levels or increased when being exposed to existing standard of care in MM. In some instances, these genes associate with existing cytogenetic subgroups and may serve as novel proteins that can be further targeted by immune-related therapies.
    IO biomarker
    |
    TP53 (Tumor protein P53) • CD20 (Membrane Spanning 4-Domains A1) • CD38 (CD38 Molecule) • CD79B (CD79b Molecule) • TNFRSF17 (TNF Receptor Superfamily Member 17) • CD79A (CD79a Molecule) • IL6R (Interleukin 6 receptor) • CD48 (CD48 Molecule) • MS4A1 (Membrane Spanning 4-Domains A1) • ROBO3 (Roundabout Guidance Receptor 3) • CD53 (CD53 Molecule) • EVI2B (Ecotropic Viral Integration Site 2B) • SLAMF7 (SLAM Family Member 7)
    over2years
    Assessment of Ecotropic Viral Integration Site 2B (EVI2B) Gene in Juvenile Myelomonocytic Leukemia and Neurofibromatosis Type 1 NF1 Tumors. (PubMed, Biochem Genet)
    When this integrated sequence was blasted into the NCBI retroviral genome database, an 87% match with the HIV-1 virus envelope gene was obtained. These preliminary results show that EVI2B might be important in NF1 tumorigenesis and leukemia.
    Journal
    |
    NF1 (Neurofibromin 1) • EVI2B (Ecotropic Viral Integration Site 2B)
    over2years
    A risk score combining co-expression modules related to myeloid cells and alternative splicing associates with response to PD-1/PD-L1 blockade in non-small cell lung cancer. (PubMed, Front Immunol)
    The significant correlation of the risk score to gene signature of tertiary lymphoid structure also implicated the possible mechanism of this predictive biomarker. Our study identified two co-expression modules related to ICB responsiveness in NSCLC and developed a risk score accordingly, which could potentially serve as a predictive biomarker for ICB response.
    Journal • PD(L)-1 Biomarker • IO biomarker
    |
    CD8 (cluster of differentiation 8) • EVI2B (Ecotropic Viral Integration Site 2B)
    almost3years
    EVI2B Is a Prognostic Biomarker and Is Correlated with Monocyte and Macrophage Infiltration in Osteosarcoma Based on an Integrative Analysis. (PubMed, Biomolecules)
    Finally, we validated the elevated expression of EVI2B in OS cell lines and OS tissue samples; these results were consistent with those of the analyses of the GSE42352 and Target-OS datasets. Our integrative bioinformatics analysis and experimental results provide clear evidence for the prognostic value of EVI2B in OS and its close relationship with monocyte and macrophage infiltration.
    Journal
    |
    CD33 (CD33 Molecule) • EVI2B (Ecotropic Viral Integration Site 2B)
    3years
    Analysis of scRNA-seq and bulk RNA-seq demonstrates the effects of EVI2B or CD361 on CD8 T cells in osteosarcoma. (PubMed, Exp Biol Med (Maywood))
    Moreover, analysis of single cell RNA-sequencing transcriptome datasets and immunohistochemical staining uncovered that EVI2B was mainly expressed on CD8 T cells and that EVI2B could promote the expression of granzyme A and K of CD8 T cells to exhibit a potent killing effect on tumor cells. Therefore, EVI2B was identified as a protective immune-related gene and contributed to good prognosis in OS patients.
    Journal
    |
    CD8 (cluster of differentiation 8) • GZMA (Granzyme A) • EVI2B (Ecotropic Viral Integration Site 2B)
    |
    CD8 expression